Health authorities in the UK have moved to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), citing concerns that the original terminology does not adequately represent the condition’s scope and impact on patients’ overall health. The renaming, which occurred earlier this year, has been accompanied by new guidance recommending annual health reviews for women with the condition to enhance long-term monitoring and care.
PMOS affects millions of women and can influence multiple body systems including hair growth, menstrual regularity, fertility and mental health. Clinical experts emphasize that the condition extends far beyond reproductive health, functioning as a cardiometabolic disorder that requires holistic management across multiple organ systems. The National Institute for Health and Care Excellence (NICE) published draft guidance in July recommending annual reviews that would monitor symptoms, track treatment effectiveness and assess longer-term health risks including diabetes and thyroid function. Final guidance is scheduled for publication on 27 January.
Women living with the condition have shared experiences of delayed diagnoses and inadequate support following initial identification. One patient described receiving a diagnosis at age 18 with minimal explanation or ongoing care, while another reported that initial concerns raised as a teenager were dismissed before finally receiving confirmation in 2025. Both emphasized that naming changes alone would not address systemic gaps in patient care and support.
Proponents of the rename argue it better captures the condition’s complexity as a multi-organ, lifelong condition affecting the whole body rather than presenting it solely as an ovarian or gynecological issue. Patients and advocates have indicated that annual reviews would be beneficial only if structured to address the broader health impacts rather than focusing narrowly on weight management or pharmaceutical interventions. Clinical professionals have stressed the importance of consistency in care delivery across fragmented healthcare services to ensure women receive comprehensive monitoring and individualized treatment approaches.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI